Wiley Matthew T. (CIK 0001759703)

Latest company ownership

VYNE - VYNE Therapeutics Inc.
Role: Chief Commercial Officer
Shares held
109,246
Last filed at
Jul 2, 2021
Confidence Score
50.0
2025Q4
Confidence Score History
2020Q1 2025Q4
BTAI - BioXcel Therapeutics, Inc.
Role: Chief Commercial Officer
Shares held
19,011
Last filed at
Oct 3, 2024
Confidence Score
50.0
2025Q4
Confidence Score History
2024Q1 2025Q4

Recent buy/sell transactions

Exec date Filing date Company Role Signal Confidence Shares % of shares Under plan? Amount (USD)
Sep 17, 2024 Oct 3, 2024 BioXcel Therapeutics, Inc. Chief Commercial Officer Sell 90.0 +14,978 371.39% ✓ $3.4K
Sep 15, 2024 Sep 17, 2024 BioXcel Therapeutics, Inc. Chief Commercial Officer Sell 37.5 -215 -5.06% ✓ $148.5
Jun 15, 2024 Jun 18, 2024 BioXcel Therapeutics, Inc. Chief Commercial Officer Sell 37.5 -244 -6.52% ✓ $308.1
Mar 15, 2024 Apr 8, 2024 BioXcel Therapeutics, Inc. CHIEF COMMERCIAL OFFICER Sell 15.0 -1,008 -25.20% ✓ $2.7K
Jun 30, 2021 Jul 2, 2021 VYNE Therapeutics Inc. Chief Commercial Officer Sell 46.3 -5,151 -4.50% ✗ $18.1K
Mar 31, 2021 Apr 2, 2021 VYNE Therapeutics Inc. Chief Commercial Officer Sell 46.3 -2,573 -2.20% ✗ $17.6K
Dec 31, 2020 Jan 5, 2021 VYNE Therapeutics Inc. Chief Commercial Officer Sell 52.5 -1,541 -0.43% ✗ $2.4K
Sep 30, 2020 Oct 2, 2020 VYNE Therapeutics Inc. Chief Commercial Officer Sell 52.5 -1,541 -0.44% ✗ $2.6K
Jun 30, 2020 Jul 2, 2020 VYNE Therapeutics Inc. Chief Commercial Officer Sell 52.5 -1,541 -0.44% ✗ $2.7K
Apr 3, 2020 Apr 7, 2020 VYNE Therapeutics Inc. Chief Commercial Officer Sell 90.0 +136,916 204.20% ✗ $1.3K
Mar 31, 2020 Apr 2, 2020 VYNE Therapeutics Inc. Chief Commercial Officer Sell 50.0 -525 -0.78% ✗ $1.4K